Yüklüyor......
Prognosis Varies by Intrinsic Tumor Subtype in Patients Treated with Ribociclib
According to a new biomarker analysis of the MONALEESA trials, intrinsic tumor subtype is an important predictor of clinical outcomes in patients with HR‐positive/HER2‐negative breast cancer treated with ribociclib and endocrine therapy.
Kaydedildi:
| Yayımlandı: | Oncologist |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
John Wiley & Sons, Inc.
2021
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7869330/ https://ncbi.nlm.nih.gov/pubmed/33399246 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13660 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|